Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.40 |
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795839 | 1.00 | KAT2B (0.43) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL3799931 | 1.00 | KAT2B (0.43) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL3798831 | 0.89 | KAT2B (0.53) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL24498375 | 0.85 | ALDH1A1 (0.43) | KAT2BBAZ2BALDH1A1ADRA2BPTGS1 | |
| SCHEMBL31122720 | 0.81 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CNTRK1 | |
| SCHEMBL2406263 | 0.81 | NTRK1 (0.42) | PDE4DPDE4APDE4BPDE4CGRM4 | |
| SCHEMBL2406266 | 0.81 | NTRK1 (0.42) | PDE4DPDE4APDE4BPDE4CGRM4 | |
| SCHEMBL2409363 | 0.81 | NTRK1 (0.42) | PDE4DPDE4APDE4BPDE4CGRM4 | |
| SCHEMBL618317 | 0.81 | MAPK8 (0.45) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL19766689 | 0.80 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | KAT2B 2283/4885BAZ2B 2679/4885PDE4D 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.